Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Pulmonology
Volume 2016, Article ID 2359437, 4 pages
http://dx.doi.org/10.1155/2016/2359437
Case Report

Severe Acute Pulmonary Toxicity Associated with Brentuximab in a Patient with Refractory Hodgkin’s Lymphoma

1Division of General Internal Medicine, Texas Tech University Health Sciences Center, El Paso, TX 79905, USA
2Division of Medical Education, Paul L. Foster School of Medicine and Texas Tech University HSC, El Paso, TX 79905, USA
3School of Medicine, Universidad Autonoma de Tamaulipas (UAT), Tampico, Mexico
4Division of Hematology and Oncology, Texas Tech University Health Sciences Center, El Paso, TX 79905, USA
5Division of Pulmonary and Critical Care Medicine, Texas Tech University Health Sciences Center, El Paso, TX 79905, USA

Received 7 January 2016; Accepted 31 March 2016

Academic Editor: Tun-Chieh Chen

Copyright © 2016 Yasmin Sabet et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. M. Newland, J. X. Li, L. E. Wasco, M. T. Aziz, and D. K. Lowe, “Brentuximab vedotin: a CD30-Directed antibody-cytotoxic drug conjugate,” Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, vol. 33, no. 1, pp. 93–104, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. C. H. Moskowitz, A. Nademanee, T. Masszi et al., “Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial,” The Lancet, vol. 385, no. 9980, pp. 1853–1862, 2015. View at Publisher · View at Google Scholar
  3. I. Uzel, M. Ozguroglu, B. Uzel et al., “Delayed onset bleomycin-induced pneumonitis,” Urology, vol. 66, no. 1, p. 195, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. N. M. Okeley, J. B. Miyamoto, X. Zhang et al., “Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate,” Clinical Cancer Research, vol. 16, no. 3, pp. 888–897, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Younes, A. K. Gopal, S. E. Smith et al., “Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma,” Journal of Clinical Oncology, vol. 30, no. 18, pp. 2183–2189, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. US Food and Drug Administration, “FDA drug safety communication: new boxed warning and contraindication for Adcetris (Brentuximab Vedotin),” 2012, http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm268969.htm.
  7. C. Turco, M. Jary, S. Kim et al., “Gemcitabine-induced pulmonary toxicity: a case report of pulmonary veno-occlusive disease,” Clinical Medicine Insights: Oncology, vol. 9, pp. 75–79, 2015. View at Publisher · View at Google Scholar · View at Scopus
  8. A. M. Sherrod, A. Brufsky, and S. Puhalla, “A case of late-onset gemcitabine lung toxicity,” Clinical Medicine Insights: Oncology, vol. 5, pp. 171–176, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. M. W. Saif, “Pulmonary toxicity associated with gemcitabine,” Journal of the Pancreas, vol. 11, no. 2, pp. 189–190, 2010. View at Google Scholar · View at Scopus
  10. Y.-C. Shen, C.-F. Chiu, K.-C. Chow, C.-L. Chen, Y.-C. Liaw, and S.-P. Yeh, “Fatal pulmonary fibrosis associated with BCNU: the relative role of platelet-derived growth factor-B, insulin-like growth factor I, transforming growth factor-β1 and cyclooxygenase-2,” Bone Marrow Transplantation, vol. 34, no. 7, pp. 609–614, 2004. View at Publisher · View at Google Scholar · View at Scopus